Location Directory

Clinical trials in Orlando, Florida

This page shows live ClinicalTrials.gov search results for Orlando, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

6846

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Alzheimers Disease
Interventions: No Intervention; Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 50 Years to 90 Years
Enrollment: 80,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 68
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 60 more

Conditions: Anastomotic Leaks, Hartmanns Stump Leakage
Interventions: Endo-SPONGE; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Sacramento, California • Orlando, Florida • Weston, Florida + 7 more

Conditions: COPD, Emphysema
Interventions: Apreo BREATHE Airway Scaffold, Optimal Medical Management (OMM); Device · Other
Lead sponsor: Apreo Health, Inc.; Industry
Eligibility: 40 Years to 84 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 18
States / cities: Birmingham, Alabama • Gilbert, Arizona • Sacramento, California + 15 more

Conditions: Stage IV Non-small Cell Lung Cancer, Stage IV Malignant Melanoma, Stage IV Small Cell Lung Cancer, Stage III Unresectable Non-Small Cell Lung Cancer, Stage IIIb-d Malignant Melanoma
Interventions: Plasma sample collection; Other
Lead sponsor: OncoHost Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 10,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 12
States / cities: Birmingham, Alabama • Jacksonville, Florida • Miami, Florida + 8 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
Interventions: Docetaxel, Lumpectomy, Mastectomy, Nab-paclitaxel, Paclitaxel, Pertuzumab, Radiation Therapy, Trastuzumab, Trastuzumab Emtansine; Drug · Procedure · Biological + 1 more
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 2,175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2038
U.S. locations: 999
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 674 more

Conditions: Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
Interventions: Biopsy, Biospecimen Collection, Capecitabine, Computed Tomography, Fludeoxyglucose F-18, Fluorouracil, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Mitomycin, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Other + 1 more
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 659
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 438 more

Conditions: Growth Hormone Deficiency (GHD)
Interventions: LUM-201, Matched Placebo (Capsules); Drug · Other
Lead sponsor: Lumos Pharma; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 31
States / cities: Birmingham, Alabama • Madera, California • Orange, California + 28 more

Conditions: Atrial Fibrillation (AF), Persistent Atrial Fibrillation, Paroxysmal Atrial Fibrillation (PAF)
Interventions: Sphere-9 Catheter Ablation; Device
Lead sponsor: Medtronic Cardiac Ablation Solutions; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 22
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 19 more

Conditions: Head and Neck Squamous Cell Carcinoma
Interventions: Petosemtamab, Investigator's Choice; Drug
Lead sponsor: Merus B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 60
States / cities: Mobile, Alabama • Prescott, Arizona • Scottsdale, Arizona + 52 more

Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
Interventions: Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer; Drug · Device
Lead sponsor: United Therapeutics; Industry
Eligibility: 40 Years and older
Enrollment: 1,850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 81
States / cities: Birmingham, Alabama • Franklin, Arizona • Phoenix, Arizona + 66 more

Conditions: Psychosis Associated With Alzheimer's Disease
Interventions: KarXT; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 148
States / cities: Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 92 more

Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions: Kerendia (Finerenone, BAY94-8862); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 4,613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 38
States / cities: Huntsville, Alabama • Phoenix, Arizona • Harrisburg, Arkansas + 33 more

Clinical trials in Orlando, Florida

Filter and sort this location

Live official records

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Endo-SPONGE for Treatment of Anastomotic or Hartmann's Stump Leakages in Lower Pelvic Area

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting